Any current/future new fundraising through debt or equity?

The company recently completed a rights issue raising around ₹40 crores. The total estimated cost for Phase 2 expansion is roughly ₹55 to ₹60 crores. For completing the expansion, management mentioned it is premature to comment on technical accounts but indicated that a nominal amount of debt may be considered to meet working capital needs for Phase 1. They are currently almost debt-free with minimal outstanding borrowings. The management is funding the Capex mostly through equity (rights issue) and aims to avoid significant additional debt. Future fundraising needs will be assessed based on p

Any current/future capex/capital investment/strategic investment?

Total capex for Unit 3 (Phase 1 and Phase 2, excluding land) is around ₹105-110 crore. Phase 1 includes a new plant with ₹110 crore approx. capex. Phase 2 of Unit 3 involves a 12,000 metric tons MCC plant with a capex of ₹55-60 crore (excluding land). The company has funded the capex largely through rights issue, minimizing significant debt. Nominal debt may be considered for working capital requirements. Land purchase (~₹6 crore) was made adjacent to the Pirana plant for warehouse/inventory storage. Management is evaluating upgrading existing units for spray-dried MCC catering to export marke

Future growth expectations in sales/revenue/volumes?

Global MCC demand is approximately 250,000 metric tons annually; Indian demand is about 50,000 metric tons. Indian demand is growing at roughly 5-7% per year, with global growth rates around 7-7.5%. New capacities totaling 30,000-40,000 metric tons likely to come online in India over the next two years. Company expects 15-20% CAGR growth over 3-5 years, with possible higher near-term growth due to ramp-up of new plants. New plants expected to achieve about 60% utilization in the first year. Peak revenue potential estimated around INR 700 crore from all three units running fully, with top-line

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a 15-20% CAGR growth over the next 3 to 5 years, with potentially higher growth in the near term. (Page 23) Peak revenue potential from the new plant is estimated around ₹150 crore, with ramp-up expected over the coming years. (Page 32, 23) CCS product segment is expected to deliver around 25% PAT margin, higher than MCC, enhancing profitability. (Page 33) Expansion plans (Phase 1 and Phase 2 of Unit 3) aim to increase capacity, supporting revenue growth without significant price pressure expected due to balanced demand-supply. (Page 21, 34) Export market growth and

Current/ Expected Orderbook/ Pending Orders?

The company already has 5 to 6 months of orders in hand for the new products. They expect to achieve around 60% capacity utilization within the first 3 to 4 months of operation. For phase one and phase two expansions, orders and business are secured, with no threat perceived to the order book. The company has good visibility and confirmed orders aiding in ramp-up plans post expansions.

IN US

Sale is live|00:00:00left today

Accent Microcell LtdQ2 FY25Pharmaceuticals & Biotechnology

Accent Microcell Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹484P/E: 24.1Market Cap: ₹1.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Global MCC demand is approximately 250,000 metric tons annually; Indian demand is about 50,000 metric tons.
→Indian demand is growing at roughly 5-7% per year, with global growth rates around 7-7.5%.
→New capacities totaling 30,000-40,000 metric tons likely to come online in India over the next two years.
→Company expects 15-20% CAGR growth over 3-5 years, with possible higher near-term growth due to ramp-up of new plants.
→New plants expected to achieve about 60% utilization in the first year.
→Peak revenue potential estimated around INR 700 crore from all three units running fully, with top-line from the new plant around INR 150 crore at peak.
→Expansion plans (phase 1 and 2 of Unit 3) supported by orders in hand, aiming for ramp-up within the next year.
→Focus on export markets alongside domestic growth to mitigate geopolitical and tariff risks.

Margin guidance

Category 3

→The company expects a 15-20% CAGR growth over the next 3 to 5 years, with potentially higher growth in the near term. (Page 23)
→Peak revenue potential from the new plant is estimated around ₹150 crore, with ramp-up expected over the coming years. (Page 32, 23)
→CCS product segment is expected to deliver around 25% PAT margin, higher than MCC, enhancing profitability. (Page 33)
→Expansion plans (Phase 1 and Phase 2 of Unit 3) aim to increase capacity, supporting revenue growth without significant price pressure expected due to balanced demand-supply. (Page 21, 34)
→Export market growth and increased domestic demand (~5-7% annually) will contribute to top-line and margin expansion. (Page 34)
→EBITDA margins for premium products are expected around 20-22%. (Page 25)
→Current focus on ramping up new capacities assures gradual improvement in earnings and profits aligned with capacity utilization. (Page 30, 23)

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company recently completed a rights issue raising around ₹40 crores.
→The total estimated cost for Phase 2 expansion is roughly ₹55 to ₹60 crores.
→For completing the expansion, management mentioned it is premature to comment on technical accounts but indicated that a nominal amount of debt may be considered to meet working capital needs for Phase 1.
→They are currently almost debt-free with minimal outstanding borrowings.
→The management is funding the Capex mostly through equity (rights issue) and aims to avoid significant additional debt.
→Future fundraising needs will be assessed based on project progress and working capital requirements while prioritizing the best interest of the company and stakeholders.

Order book

Yes

→The company already has 5 to 6 months of orders in hand for the new products.
→They expect to achieve around 60% capacity utilization within the first 3 to 4 months of operation.
→For phase one and phase two expansions, orders and business are secured, with no threat perceived to the order book.
→The company has good visibility and confirmed orders aiding in ramp-up plans post expansions.

Capex plans

Yes

→Total capex for Unit 3 (Phase 1 and Phase 2, excluding land) is around ₹105-110 crore.
→Phase 1 includes a new plant with ₹110 crore approx. capex.
→Phase 2 of Unit 3 involves a 12,000 metric tons MCC plant with a capex of ₹55-60 crore (excluding land).
→The company has funded the capex largely through rights issue, minimizing significant debt.
→Nominal debt may be considered for working capital requirements.
→Land purchase (~₹6 crore) was made adjacent to the Pirana plant for warehouse/inventory storage.
→Management is evaluating upgrading existing units for spray-dried MCC catering to export markets as part of Phase 2 expansion.
→Adequate land is available currently for Phase 1 and 2; further expansions will be taken as per future needs and stakeholder interests.

How does Accent Microcell Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Accent Microcell Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Accent Microcell Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio